Home        Sitemap        Contact us 
Discovery Pipeline
You are in: » Pipeline  » Discovery Pipeline
Arrien Pharmaceuticals Pipeline Overview
Arrien Pharmaceuticals a small molecule targeted therapeutics drug discovery and development company, working towards targeting kinase signaling and nuclear receptor pathways - A target class in treating Inflammation, Autoimmune, Cancer and CNS/Neurodegenerative diseases.
ROR-γt (Psoriasis, RA and MS)

Partner: Worldwide exclusive license granted to Boston Pharmaceuticals in 2017.

Mechanism of Action: The nuclear hormone receptor retinoic acid-related orphan receptor gamma t (ROR-γt) is a transcription factor (TF) specific to TH17 cells that produce interleukin (IL)-17 and have been implicated in a wide range of autoimmunity.

The pipeline above provides the most advanced programs in the areas of Inflammation/Autoimmune, Oncology and CNS/Neurodegenerative diseases and stages in the drug development process.

Copyright © 2011, Arrien Pharmaceuticals, LLC. All rights reserved.